# Shanghai Yipu Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-yipu-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.epiprobe.com
- Latest round: Series A (Nov 5, 2020)
- Investors on record: 1

## About

Established in 2018 and based in Shanghai, China, Shanghai Yipu Biotechnology Co., Ltd. is a healthcare company that focuses on providing molecular cancer tumor diagnostic services. The company has 20+ clinical partners, 21,000+ clinical samples with double-blind cumulative validation, 25+ cumulative patent applications and 25+ STAMP® all-cancer markers covering cancer types. The Chief Scientist Officer, Professor Wenqiang Yu, graduated from Johns Hopkins University and has nearly 30 years of experience in basic and clinical research in epigenetics. Ms. Lin Hua, CEO, graduated from Shanghai Jiao Tong University and is a founding partner of Qiaobei Capital with over 10 years of experience in corporate services. The company published a new sequencing method for DNA methylation in January 2019 and released three products for whole cancer, bladder cancer and cervical cancer in June 2020.

The company self-developed products such as whole cancer markers, methylation platform, STAMP™ Whole Cancer Screening Product, STAMP™ Bladder Cancer Screening Product and STAMP™ Cervical Cancer Screening Product. The company self-developed molecular tumor detection technology use in the field of early tumor screening, adjuvant diagnosis, efficacy assessment and recurrence detection.

## Funding rounds

- Series A, Nov 5, 2020 — Chobe Capital

## Investors

- Chobe Capital (https://capitalatlas.ai/funds/chobe-capital) — Series A